Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



### Shanghai HeartCare Medical Technology Corporation Limited

#### 上海心瑋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

# VOLUNTARY ANNOUNCEMENT UNAUDITED OPERATING STATISTICS FOR THE PERIOD FROM JANUARY 1, 2021 TO DECEMBER 31, 2021

This announcement is made by Shanghai HeartCare Medical Technology Corporation Limited (the "Company", together with its subsidiaries, the "Group") on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board of directors (the "Board") of the Company is pleased to announce certain unaudited operating statistics of the Group for the year ended December 31, 2021, and the comparative figures as set out below.

For the period from January 1 to December 31,		
<b>2021</b> RMB' million	2020 RMB' million (approximate)	Change %
90.1	14.6	517%

The increase in revenue was attributable to: (i) significantly increased sales revenue of the full suite of commercialized ischemic stroke thrombectomy devices mainly including the Company's Captor<sup>TM</sup> thrombectomy device and ExtraFlex<sup>TM</sup> distal access catheter; and (ii) additional revenue generated by the commercialization of intracranial stenosis treatment devices including OpenVas intracranial balloon dilatation catheter and ThruVas carotid artery balloon dilatation catheter.

Revenue

The Company is still in the process of finalizing the annual results of the Group for the year ended December 31, 2021. The above operating information is provided for investors' reference only and it shall not be taken as a measure or indication of the Group's future financial performance.

### SHAREHOLDERS AND POTENTIAL INVESTORS OF THE COMPANY ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SHARES OF THE COMPANY.

## By order of the Board Shanghai HeartCare Medical Technology Corporation Limited Wang Guohui

Chairman of the Board

Shanghai, March 1, 2022

As at the date of this announcement, the executive Directors are Mr. Wang Guohui and Ms. Zhang Kun; the non-executive Directors are Mr. Ding Kui, Mr. Chen Gang and Mr. Ouyang Xiangyu; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.